Literature DB >> 17150018

Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors.

Steve H Thorne1.   

Abstract

In order to more effectively treat cancer, targeted delivery of therapeutic agents will be needed. The creation of delivery vehicles capable of locating and entering tumors before delivering a therapeutic payload will, therefore, enable the design of more beneficial and less toxic treatment platforms. Although nanoparticles, microbubbles and liposomes may also partially address these issues, the use of biological agents as delivery vehicles presently holds much promise. Through the hijacking of natural pathogen or cell trafficking pathways it is possible to actively target such agents to the tumor; they are then capable of selective replication (multiplying their therapeutic potential) and may be directly cytolytic themselves and/or may be utilized to deliver therapeutic genes. These agents, such as oncolytic viruses, attenuated bacteria and eukaryotic cells (cellular immunotherapeutics and progenitor and stem cells) will be discussed along with the mechanisms employed to deliver them systemically to tumors, including disseminated disease and micrometsastases.

Entities:  

Mesh:

Year:  2007        PMID: 17150018     DOI: 10.1517/14712598.7.1.41

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  12 in total

Review 1.  Non-invasive cell tracking in cancer and cancer therapy.

Authors:  Hao Hong; Yunan Yang; Yin Zhang; Weibo Cai
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 2.  Immunotherapeutic potential of oncolytic vaccinia virus.

Authors:  Steve H Thorne
Journal:  Immunol Res       Date:  2011-08       Impact factor: 4.505

3.  Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Authors:  Padma Sampath; Jun Li; Weizhou Hou; Hannah Chen; David L Bartlett; Steve H Thorne
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

Review 4.  Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.

Authors:  Candice Willmon; Kevin Harrington; Timothy Kottke; Robin Prestwich; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

Review 5.  Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.

Authors:  M Mimeault; S K Batra
Journal:  Panminerva Med       Date:  2008-03       Impact factor: 5.197

Review 6.  Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies.

Authors:  M Mimeault; R Hauke; S K Batra
Journal:  Clin Pharmacol Ther       Date:  2007-09-05       Impact factor: 6.875

Review 7.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15

8.  CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy.

Authors:  Steve H Thorne; Yoram Barak; Wenchuan Liang; Michael H Bachmann; Jianghong Rao; Christopher H Contag; A Matin
Journal:  Mol Cancer Ther       Date:  2009-02-03       Impact factor: 6.261

Review 9.  A bibliometric review of oncolytic virus research as a novel approach for cancer therapy.

Authors:  Amir Sasan Mozaffari Nejad; Tehjeeb Noor; Ziaul Haque Munim; Mohammad Yousef Alikhani; Amir Ghaemi
Journal:  Virol J       Date:  2021-05-12       Impact factor: 4.099

10.  Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Authors:  David H Kirn; Yaohe Wang; Fabrice Le Boeuf; John Bell; Steve H Thorne
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.